Friday, October 30, 2026
ExploreSearch
Finance Via News

Banking M&A

3 articles

Columbia Financial Raises $1.67B in IPO, Closes Northfield Bancorp Buy One Day Later

Columbia Financial Raises $1.67B in IPO, Closes Northfield Bancorp Buy One Day Later

Columbia Financial priced its second-step conversion at $10.00 per share, selling over 167 million shares to raise roughly $1.67 billion ahead of a July 21, 2026 Nasdaq debut. The company closes its acquisition of Northfield Bancorp on July 20, 2026, offering shareholders $14.25 cash or 1.425 shares per Northfield share.

LM Salvado•
ABN AMRO Acquires NIBC as European Banks Pursue Scale in Consolidation Wave

ABN AMRO Acquires NIBC as European Banks Pursue Scale in Consolidation Wave

ABN AMRO's acquisition of NIBC and RBC's $13.5B purchase of HSBC Canada mark a European banking consolidation wave as institutions seek scale advantages. Leadership transitions at ING and ABN AMRO accompany structural changes, while Bank of Åland distributes EUR 2.75 per share dividends amid sector repositioning.

ViaNews Editorial Team (Finance)•
PNC completes six acquisitions in four years as regional banks race to offset margin pressure

PNC completes six acquisitions in four years as regional banks race to offset margin pressure

PNC Financial closed deals for BBVA USA, Linga, Signature Bank assets, and gained approval for FirstBank and Aqueduct Capital Group between 2021-2025. The consolidation wave reflects industry-wide pressure on net interest margins, with PNC forecasting just 1.5% sequential NII growth in Q4 2025 despite its aggressive expansion.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com